Simplistic models of #IntellectualProperty get in the way of building a biopharmaceutical company. Here I discuss how going #OpenScience can lead to proprietary rights later on: www.lifescienceleader.com/doc/open-sci... @conscience-network.bsky.social @tridentpct.bsky.social
By sharing early-stage tools and data openly, life sciences companies can minimize duplication and de-risk R&D without risking exclusive rights over valuable assets, writes Richard Gold.
